Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia
International Journal of Molecular Sciences · 14.03.2024 · 25 (6) · 3307
DOI: 10.3390/ijms25063307 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.03.2024. Verfasst von Andrew Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Collings Stevens Chronic Leukemia Research Laboratory, Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC V5Z 1L3, Canad…. Hauptthemen laut MEDLINE: Fusion Proteins, bcr-abl, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research, Canadian Cancer Society.
Abstract (Originalsprache)
Chronic myeloid leukemia is a multistep, multi-lineage myeloproliferative disease that originates from a translocation event between chromosome 9 and chromosome 22 within the hematopoietic stem cell compartment. The resultant fusion protein BCR::ABL1 is a constitutively active tyrosine kinase that can phosphorylate multiple downstream signaling molecules to promote cellular survival and inhibit apoptosis. Currently, tyrosine kinase inhibitors (TKIs), which impair ABL1 kinase activity by preventing ATP entry, are widely used as a successful therapeutic in CML treatment. However, disease relapses and the emergence of resistant clones have become a critical issue for CML therapeutics. Two main reasons behind the persisting obstacles to treatment are the acquired mutations in the ABL1 kinase domain and the presence of quiescent CML leukemia stem cells (LSCs) in the bone marrow, both of which can confer resistance to TKI therapy. In this article, we systemically review the structural and molecular properties of the critical domains of BCR::ABL1 and how understanding the essential role of BCR::ABL1 kinase activity has provided a solid foundation for the successful development of molecularly targeted therapy in CML. Comparison of responses and resistance to multiple BCR::ABL1 TKIs in clinical studies and current combination treatment strategies are also extensively discussed in this article.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Collings Stevens Chronic Leukemia Research Laboratory, Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
- Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
- Department of Medical Genetics, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
ORCID-Profile: Xiaoyan Jiang
Förderung
- CIHR
- Canadian Institutes of Health Research
- Canadian Cancer Society
- Leukemia & Lymphoma Society of Canada
- Collings Stevens Chronic Leukemia Research Fund
Zitieren
APA
Wu, A., Liu, X., Fruhstorfer, C., & Jiang, X. (2024). Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia. International Journal of Molecular Sciences, 25(6), 3307. https://doi.org/10.3390/ijms25063307
Vancouver
Wu A, Liu X, Fruhstorfer C, Jiang X. Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia. International Journal of Molecular Sciences. 2024;25(6):3307. doi:10.3390/ijms25063307
BibTeX
@article{Wu2024,
author = {Wu, Andrew and Liu, Xiaohu and Fruhstorfer, Clark and Jiang, Xiaoyan},
title = {Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {6},
pages = {3307},
doi = {10.3390/ijms25063307}
}
EUVIMED